Journal article · 2025 · Open access

Reanalysis of in vivo drug synergy validation study rules out synergy in most cases

Olaf van Tellingen, Renée X. de Menezes

Nature Communications, 16(1), 8534 · Published 30 September 2025 · DOI 10.1038/s41467-025-62617-w

Free PDFView at the publisherCite this paper

In brief

“Reanalysis of in vivo drug synergy validation study rules out synergy in most cases” is a 2025 journal article by Olaf van Tellingen and Renée X. de Menezes, published in Nature Communications. OpenAlex counts 5 citations as of 15 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Communications.

Citations
5
Most cited in
2026 (4)
Field-weighted impact
1.43
References
13
Authors
2

Abstract

Narayan et al. 1 described the development of an in silico platform (“Drug Atlas”) to predict synergistic drug combinations and claimed successful in vivo validation in five models. Demonstrating the impact of a given drug in in vivo models is challenging because effect sizes are often small 2 . Because of the inherent variability in tumor outgrowth in vivo, achieving adequate statistical power requires sufficiently sized groups. As the experimental complexity increases, for example, when assessing combination effects, the minimum required group size also increases. A statistically sound distinction between additive and synergistic drug effects requires even larger datasets, as do comparisons across multiple drug combinations of drugs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

van Tellingen, O., & de Menezes, R. X. (2025). Reanalysis of in vivo drug synergy validation study rules out synergy in most cases. Nature Communications, 16(1), 8534. https://doi.org/10.1038/s41467-025-62617-w

MLA 9

van Tellingen, Olaf, and Renée X. de Menezes. “Reanalysis of in vivo drug synergy validation study rules out synergy in most cases.” Nature Communications, vol. 16, no. 1, 2025, p. 8534. https://doi.org/10.1038/s41467-025-62617-w.

Chicago

van Tellingen, Olaf and Renée X. de Menezes. 2025. “Reanalysis of in vivo drug synergy validation study rules out synergy in most cases.” Nature Communications 16 (1): 8534. https://doi.org/10.1038/s41467-025-62617-w.

Harvard

van Tellingen, O. and de Menezes, R. X. (2025) ‘Reanalysis of in vivo drug synergy validation study rules out synergy in most cases’, Nature Communications, 16(1), p. 8534. doi:10.1038/s41467-025-62617-w.

IEEE

O. van Tellingen and R. X. de Menezes, “Reanalysis of in vivo drug synergy validation study rules out synergy in most cases,” Nature Communications, vol. 16, no. 1, p. 8534, 2025, doi: 10.1038/s41467-025-62617-w.

BibTeX

@article{vantellingen2025reanalysis,
  title     = {{Reanalysis of in vivo drug synergy validation study rules out synergy in most cases}},
  author    = {van Tellingen, Olaf and de Menezes, Renée X.},
  journal   = {Nature Communications},
  year      = {2025},
  volume    = {16},
  number    = {1},
  pages     = {8534},
  doi       = {10.1038/s41467-025-62617-w},
  url       = {https://doi.org/10.1038/s41467-025-62617-w}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • drug synergy
  • drug combination effects
  • in vivo validation
  • statistical power
  • sample size requirements

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

van Tellingen, O., & de Menezes, R. X. (2025). Reanalysis of in vivo drug synergy validation study rules out synergy in most cases. Nature Communications, 16(1), 8534. https://doi.org/10.1038/s41467-025-62617-w

How many times has this paper been cited?

5 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Nature Communications.

Who wrote this paper?

Olaf van Tellingen, Renée X. de Menezes.

What is the DOI of this paper?

10.1038/s41467-025-62617-w. The permanent link is https://doi.org/10.1038/s41467-025-62617-w.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.